These data support the idea that Bin1-SH3 inhibits Dyn2 and raises the possibility that enhanced Dyn2 activity could be part of the pathogenesis of CNM associated with Bin1 mutations. The gene discussed is BIN1; the disease is centronuclear myopathy.